{"entity":{"id":"nct06643884","kind":"trial","name":"Suprachoroidal Administration in Subjects With Metastases to the Choroid","aka":[],"tldr":"A phase 2 trial of AU-011 in advanced solid tumours, run by Aura Biosciences, now recruiting.","summary":"Suprachoroidal Administration in Subjects With Metastases to the Choroid is a phase 2 interventional study registered as NCT06643884 by Aura Biosciences, with 24 participants planned, started 2024-12-16 and due to reach its primary completion in 2026-11-30. Interventions recorded: AU-011, SCS Microinjector and Laser.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06643884","url":"https://clinicaltrials.gov/study/NCT06643884"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["aura-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06643884","phase":"2","setting":"A Phase 2, Open-Label, Dose Escalation Trial Assessing the Safety, Tolerability, and Treatment Effect of Belzupacap Sarotalocan (AU-011) With Suprachoroidal Administration in Subjects With Metastases to the Choroid","sponsor":"Aura Biosciences","enrolled":24,"outcomes":[]},"route":"/trials/nct06643884/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"aura-biosciences","kind":"company","name":"Aura Biosciences","route":"/companies/aura-biosciences/"}]}}